Sanjeev Pathak, MD

Long-Term Treatment With Adjunctive Buprenorphine/Samidorphan Combination in Patients With Major Depressive Disorder: Interim Phase 3 Study Results

Introduction: Buprenorphine/samidorphan (BUP/SAM) is an investigational opioid system modulator demonstrating efficacy versus placebo as an adjunctive treatment for major depressive disor...

Sanjeev Pathak , MD;

Arielle Stanford , MD;

Maurizio Fava , MD, PhD;

Asli Memisoglu , ScD;

Madhukar Trivedi , MD;

William Martin , PhD;

Michael Thase , MD;

J. Alexander Bodkin , MD;

Amy Claxton , PhD;

03/01/2019

Clinical Evaluation of Abuse Potential of Buprenorphine /Samidorphan (BUP/SAM) Combination

Introduction: Buprenorphine (BUP)/samidorphan (SAM) combination is an opioid system modulator being investigated as adjunctive treatment for major depressive disorder (MDD). The human abu...

Narinder Nangia , PhD;

Arielle Stanford , MD;

Andrew J. Cutler , MD;

Sanjeev Pathak , MD;

Sanjay Mathew , MD;

Michael E. DeBakey ;

Beatrice Setnik , PhD;

03/01/2019

A Buprenorphine-Samidorphan Combination (BUP/SAM) for Adjunctive Treatment of Major Depressive Disorder: Results From Analyses of US Patients From Three Placebo-Controlled Trials

Background: Buprenorphine/samidorphan (BUP/SAM) is an investigational opioid system modulator for adjunctive treatment of major depressive disorder. To account for differences in treatmen...

William Martin , PhD;

Elliot Ehrich , MD;

Michael Thase , MD;

Maurizio Fava , MD, PhD;

Madhukar Trivedi , MD;

Amy Claxton , PhD;

Sanjeev Pathak , MD;

Arielle Stanford , MD;

Asli Memisoglu , ScD;

02/28/2019

Pimavanserin treatment of hallucinations and delusions in patients with Parkinson’s disease dementia: post hoc analysis of the HARMONY trial

Abstract: Introduction: Pimavanserin 34 mg is approved in the US to treat hallucinations and delusions associated with Parkinson’s Disease psychosis (PDP). The efficacy and safety of pima...

Christopher Jaccoma ;

Sanjeev Pathak , MD;

01/19/2023